Changes for page Merck & Co

Last modified by Asif Farooqui on 2023/04/17 02:47
From version < 7.1 >
edited by Asif Farooqui
on 2023/03/28 11:47
To version < 8.1
edited by Asif Farooqui
on 2023/04/17 02:47
<
Change comment: There is no comment for this version

Summary

Details

Page properties
Content
... ... @@ -8,7 +8,6 @@
8 8  * The company delivers health solutions through biologic therapies, vaccines and animal health products.
9 9  * The company recently acquire Imago BioSciences
10 10  
11 -
12 12  [[image:MRK0.webp||height="326" width="722"]]
13 13  
14 14  
... ... @@ -17,6 +17,14 @@
17 17  
18 18  = Recent Developments =
19 19  
19 +**Merck to buy Prometheus Biosciences**{{footnote}}https://www.merck.com/news/merck-strengthens-immunology-pipeline-with-acquisition-of-prometheus-biosciences-inc/{{/footnote}}
20 +
21 +April 16, 2023; Merck known as MSD outside the United States and Canada, and Prometheus Biosciences, Inc. (“Prometheus”) (Nasdaq: RXDX) today announced that the companies have entered into a definitive agreement under which Merck, through a subsidiary, has agreed to acquire Prometheus for $200.00 per share in cash for a total equity value of approximately $10.8 billion.
22 +
23 +
24 +Prometheus is a clinical-stage biotechnology company pioneering a precision medicine approach for the discovery, development, and commercialization of novel therapeutic and companion diagnostic products for the treatment of immune-mediated diseases. The company’s lead candidate, PRA023, is a humanized monoclonal antibody (mAb) directed to tumor necrosis factor (TNF)-like ligand 1A (TL1A), a target associated with both intestinal inflammation and fibrosis.
25 +
26 +
20 20  **US FDA Approves Intramuscular Administration for Merck’s MMRV Family of Vaccines**{{footnote}}https://www.merck.com/news/us-fda-approves-intramuscular-administration-for-mercks-mmrv-family-of-vaccines-m-m-rii-measles-mumps-and-rubella-virus-vaccine-live-varivax-varicella-virus-vaccine-live-and-proquad/{{/footnote}}
21 21  
22 22  March 6, 2023; Merckx known as MSD outside of the United States and Canada, announced that the U.S. Food and Drug Administration (FDA) has approved the addition of the intramuscular (IM) route of administration to the United States Product Insert (USPI) for Merck’s MMRV family of vaccines: M-M-R®II, VARIVAX®, and ProQuad®.
This site is funded and maintained by Fintel.io